| Name | Title | Contact Details |
|---|
Biomedical International is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrated Health Plan Inc is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Northern Arizona Regional Behavioral Health Authority (NARBHA) was founded in 1967. It is a private, not-for-profit managed care corporation designated by the Arizona Department of Health Services as being responsible for the planning, implementation, funding, monitoring and administration of publicly funded comprehensive behavioral health services in Northern Arizona. NARBHA serves over 700,000 people throughout 62,000 square miles (or ½ of the state) of northern Arizona, including the Hopi Reservation. NARBHA subcontracts with ten Responsible Agencies (RAs), over 70 additional behavioral health providers, and operated under Memorandums of Understanding (MOU) with ten Native American tribes, offering choice of services to members throughout northern Arizona. NARBHA contracts with NAZCARE, Recovery Innovations of Arizona (RIAZ), and MIKID to offer peer and family support programs and services. Consumer/ family involvement is included on eight standing NARBHA and numerous ad hoc NARBHA Committees and Workgroups.
Biomet Tri-State Orthopedics is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs. Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component. We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.